Latest / PETRI DISH PERSPECTIVES
Episode 77: Revolution Medicines
Send us Fan Mail
In this episode of Petri Dish Perspectives, we explore Revolution Medicines, the precision oncology company that spent over a decade trying to drug one of cancer’s most notorious targets: RAS. With mutations present in roughly 30% of all new cancer diagnoses, including pancreatic, lung, and colorectal cancers, RAS has long been considered undruggable. Revolution bet their entire company on proving that wrong.
We break down the science behind their tricomplex inhibitor platform, the three lead drugs in their pipeline, daraxonrasib, elironrasib, and zoldonrasib, and the…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.